Does Array Biopharma Inc (NASDAQ:ARRY) Have Gas After Even More Sellers Involved?

October 2, 2018 - By Louis Casey

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Investors sentiment decreased to 1.12 in 2018 Q2. Its down 0.62, from 1.74 in 2018Q1. It turned negative, as 33 investors sold Array BioPharma Inc. shares while 57 reduced holdings. 29 funds opened positions while 72 raised stakes. 190.66 million shares or 0.50% more from 189.71 million shares in 2018Q1 were reported.
First Trust Advsrs Limited Partnership accumulated 0% or 135,467 shares. Bailard Inc holds 28,200 shares or 0.03% of its portfolio. Great West Life Assurance Can owns 22,164 shares. Blackrock accumulated 0.01% or 16.92 million shares. Ontario Teachers Pension Plan Board reported 23,800 shares. 33,700 are owned by Creative Planning. Meeder Asset Management holds 1,064 shares. Moreover, Artal Gru has 0.71% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 2.00M shares. Thompson Davis And Communication Inc reported 125 shares. Loring Wolcott And Coolidge Fiduciary Llp Ma has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Retail Bank Of Montreal Can has 4,043 shares for 0% of their portfolio. Raymond James Services holds 16,087 shares. Macquarie Group Limited holds 929,678 shares or 0.03% of its portfolio. Jnba Fincl Advsrs holds 0% or 500 shares. Manufacturers Life The holds 0% or 150,358 shares.

Since April 18, 2018, it had 0 insider purchases, and 13 selling transactions for $8.79 million activity. VAN LUNSEN GIL J sold $265,684 worth of stock. 50,000 shares were sold by LEFKOFF KYLE, worth $872,500. The insider Haddock Jason sold 20,000 shares worth $278,400. Shares for $420,450 were sold by Sandor Victor. $3.31 million worth of stock was sold by Squarer Ron on Wednesday, June 27.

The stock of Array Biopharma Inc (NASDAQ:ARRY) registered an increase of 8.25% in short interest. ARRY’s total short interest was 14.63 million shares in October as published by FINRA. Its up 8.25% from 13.51 million shares, reported previously. With 2.24M shares average volume, it will take short sellers 7 days to cover their ARRY’s short positions.

The stock decreased 1.67% or $0.255 during the last trading session, reaching $15.055. About 832,575 shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 38.92% since October 2, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.21 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Among 4 analysts covering Array Biopharma (NASDAQ:ARRY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Array Biopharma had 5 analyst reports since May 10, 2018 according to SRatingsIntel. The company was maintained on Thursday, May 10 by Cowen & Co. Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Tuesday, June 5. Cowen & Co has “Buy” rating and $1900 target. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Monday, June 25 by Piper Jaffray. The firm has “Outperform” rating given on Thursday, June 28 by Wells Fargo. Cantor Fitzgerald maintained it with “Overweight” rating and $26 target in Monday, June 25 report.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by:, which released: “Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug” on September 07, 2018.‘s article titled: “Arrapy Bio’s Braftovi + Mektovi OK’d in Europe” and published on September 20, 2018 is yet another important article.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.